- ASSOCIATE PROFESSOR | Dermatology
- Hospital Affiliations
- Mount Sinai Beth Israel
- The Mount Sinai Hospital
- Mount Sinai St. Luke's and Mount Sinai West
Andrew F. Alexis, MD, MPH is the Chair of the Department of Dermatology at Mount Sinai St. Luke’s and Mount Sinai West. He is also Associate Professor of Dermatology at the Icahn School of Medicine at Mount Sinai. As Director of the Skin of Color Center, he is actively involved in advancing patient care, research, and education pertaining to dermatologic disorders that are prevalent in ethnic skin.
Dr. Alexis received his medical degree from Columbia University College of Physicians & Surgeons and his Master of Public Health at Columbia University’s Mailman School of Public Health. He completed his dermatology residency at Weill Cornell Medical Center, followed by a fellowship in dermatopharmacology at New York University School of Medicine.
Dr. Alexis has published more than 70 articles in peer-reviewed journals including the British Journal of Dermatology, Journal of the American Academy of Dermatology, and Archives of Dermatology among others. He has co-edited two text books on dermatology for skin of color - Skin of Color A Practical Guide to Dermatologic Diagnosis and Treatment (Springer Publishing 2013) and Ethnic Dermatology: Principles and Practice (Wiley-Blackwell 2013) – and authored 10 book chapters.
Dr. Alexis has held numerous leadership positions in professional organizations including Past President of the New York Academy of Medicine Dermatology Section, Secretary/Treasurer of the Skin of Color Society and Chair of the Diversity Task Force Committee for the American Academy of Dermatology. He currently serves as President of the New York Dermatological Society, Chair of the Scientific Committee of the Skin of Color Society, and is a member of the Board of Directors of the Cicatricial Alopecia Research Foundation.
Dr. Alexis has appeared on ABC, CBS, NBC, and FOX television news programs and has been quoted in numerous leading publications, including the New York Times, Wall Street Journal, Forbes, Allure, and Essence. He is listed in Castle Connolly’s Top Doctors ™ and Super Doctors®.
Latest News where Dr Alexis is quoted:
Trump Takes the Hair-Growth Drug Propecia. How Does It Work? https://www.nytimes.com/2017/02/02/health/donald-trump-hair-growth-drug-propecia.html
Many Ways to Shear a Man http://www.nytimes.com/2010/06/17/fashion/17skinside.html
In Search of a Perfect Shave http://www.wsj.com/articles/SB10000872396390444270404577607183291333266
The Doctors are In
Barbers May Help Men of Color Spot Hair Follicle Problems https://www.reuters.com/article/us-health-barbers/barbers-may-help-men-of-color-spot-hair-follicle-problems-idUSKBN1D325W
Darker Skin can Hide Early Signs of Cancerhttp://www.ny1.com/nyc/all-boroughs/health-and-medicine/2015/05/26/darker-skin-can-hide-early-skin-cancer-signs.html
7 Sunscreen Mistakes You're Probably Making
What You Need to Know About Skin Cancer, And How to Protect Yourself
Why Melanoma Isn't the Only Kind of Skin Cancer You Need to Worry About http://www.menshealth.com/health/non-melanoma-skin-cancers
Dermatologist Suggests Skin Tone Should Impact Treatment https://www.michigandaily.com/section/news/mlk-dermatology
Ethnic Considerations in Features of Facial Aging http://www.healio.com/dermatology/aesthetic-cosmetic-surgery/news/online/%7B454543e0-1601-4b6c-8ea9-dffbcf8ad835%7D/video-ethnic-considerations-in-features-of-facial-aging
You May Not Have Heard of This Painful Skin Disease—But It's Actually Pretty Common
FDA Approves New Psoriasis Drug That Promises Huge Skin Improvement
Medical Bills another Burden for Eczema Patients: Study
Daily Checkup: Skin Cancer Strikes 1 In 5 Americans, Yet It Remains Highly Treatable, Especially If Caught Early
Higher response rate seen with T-VEC in advanced melanoma
Mouse Study Hints at Treatment for Eczema
New Drug Shows Promise against Psoriasis
Study Reveals Cause of Itch in Eczema, Hints at Possible Treatment
American Board of Dermatology
- Acne Scars
- Age Spots
- Alopecia Areata
- Atopic Dermatitis
- Botulinum Injections-Cosmetic
- Chemical Peels
- Fractionated Laser Resurfacing
- Inflammatory Skin Diseases
- Laser Hair Removal
- Laser Resurfacing
- Mole Removal
- Pigmentary Disorders
- Pigmentation Laser
- Pseudofolliculitis Barbae
- Razor Bumps
- Skin Biopsy
- Skin Cancer Screening
- Skin Care
- Skin Lesion Removal
- Skin Rejuvenation
- Skin Tightening
- Skin of Color
- Soft Tissue Augmentation
- Vascular Laser
MD, Columbia University College of Physicians & Surgeons
Internship, Internal Medicine
St. Vincent's Hospital [CLOSED]
Internship, Internal Medicine
St. Vincent's Hospital [CLOSED]
Weill Cornell Medical College
New York University School of Medicine
To Determine the Compliance Usage Rate and Efficacy of a Coconut Scented Lotion versus a Fragrance Free Lotion in Female Subjects with Moderate to Severe Dry Skin with Bilateral Itch
To Determine the Compliance Usage Rate and Efficacy of a Coconut Scented Lotion versus a Fragrance Free Lotion in Female Subjects with Moderate to Severe Dry Skin with Bilateral Itch.
Dr. Alexis is conducting a research study to Determine the Compliance Usage Rate and Efficacy of a Coconut Scented Lotion versus a Fragrance Free Lotion in Female Subjects with Moderate to Severe Dry Skin with Bilateral Itch.
A Prospective, Phase 2a Study to Evaluate the Effectiveness and Safety of DPCP Ointment (Samcyprone™) on the Clearance of Verruca Vulgaris (Common Warts) in Subjects Ages 18 – 65 Years
This study is looking at the effectiveness of an investigational drug in the treatment of common warts. This includes warts on the hands and feet but NOT genital warts. Patients must be in good health, ages 18-65 years. Patients must be available for weekly appointments. The s...
A randomized, double-blind, placebo-controlled, parallel-group, multicenter study to evaluate the effect of secukinumab on aortic vascular inflammation and cardiometabolic biomarkers after 12 weeks of treatment, compared to placebo, and up to 52 weeks of treatment with secukinumab in adult subjects with moderate to severe chronic plaque-type psoriasis
We are studying an injectable medication, secukinumab (Cosentyx), in the treatment of moderate to severe plaque psoriasis. The trial lasts for 52 weeks. Patients will undergo 3 FDG-PET/CT scans during the study. Patients may be eligible for this study if they:
A Phase 3 Multi-Center, Randomized, Double- Blinded, Vehicle-Controlled, Parallel Group Study Comparing the Efficacy, Tolerability and Safety of Once Daily SB204 and Vehicle Gel in the Treatment of Acne Vulgaris
This clinical trial, sponsored by Novan, is currently underway to evaluate an investigational drug using Nitric Oxide for the treatment of acne vulgaris on the face. This study will last approximately 3 months. Individuals may be candidates for this study if they:
Genetics of Sporadic Keloids in African Americans
Keloids are raised scars on the skin that follow minor injury. Keloids occur in people of all racial backgrounds but are particularly common among African Americans. Some families have multiple members with keloids, suggesting a possible genetic basis. We wish to come to a better...
Alexis AF. Lasers and light-based therapies in ethnic skin: treatment options and recommendations for Fitzpatrick skin types V and VI. The British journal of dermatology 2013 Oct; 169 Suppl 3.
Hudgens S, Harper JC, Daniels SR, Banderas B, Varon S, Alexis AF. Validation of a New Patient-Reported Outcome Measure for Facial Acne: The Acne Symptom and Impact Scale (ASIS). Journal of drugs in dermatology : JDD 2015 Jun; 14(6).
Alexis AF, Blackcloud P. Psoriasis in skin of color: epidemiology, genetics, clinical presentation, and treatment nuances. The Journal of clinical and aesthetic dermatology 2014 Nov; 7(11).
Callender VD, Alexis AF, Daniels SR, Kawata AK, Burk CT, Wilcox TK, Taylor SC. Racial differences in clinical characteristics, perceptions and behaviors, and psychosocial impact of adult female acne. The Journal of clinical and aesthetic dermatology 2014 Jul; 7(7).
Alexis AF. Acne vulgaris in skin of color: understanding nuances and optimizing treatment outcomes. Journal of drugs in dermatology : JDD 2014 Jun; 13(6).
Alexis A, Daniels SR, Johnson N, Pompilus F, Burgess SM, Harper JC. Development of a new patient-reported outcome measure for facial acne: the Acne Symptom and Impact Scale (ASIS). Journal of drugs in dermatology : JDD 2014 Mar; 13(3).
Alexis AF. Laser resurfacing for treatment of acne scarring in Fitzpatrick skin types V to VI: practical approaches to maximizing safety. Cutis 2013 Dec; 92(6).
Alexis AF, Blackcloud P. Natural ingredients for darker skin types: growing options for hyperpigmentation. Journal of drugs in dermatology : JDD 2013 Sep; 12(9 Suppl).
Clark CM, Silverberg JI, Alexis AF. A retrospective chart review to assess the safety of nonablative fractional laser resurfacing in Fitzpatrick skin types IV to VI. Journal of drugs in dermatology : JDD 2013 Apr; 12(4).
Alexis AF. Dermatologic disorders in skin of color: moving toward a better understanding. Journal of drugs in dermatology : JDD 2013 Apr; 12(4).
Alexis AF, Alam M. Racial and ethnic differences in skin aging: implications for treatment with soft tissue fillers. Journal of drugs in dermatology : JDD 2012 Aug; 11(8).
Physicians and scientists on the faculty of the Icahn School of Medicine at Mount Sinai often interact with pharmaceutical, device and biotechnology companies to improve patient care, develop new therapies and achieve scientific breakthroughs. In order to promote an ethical and transparent environment for conducting research, providing clinical care and teaching, Mount Sinai requires that salaried faculty inform the School of their relationships with such companies.
Below are financial relationships with industry reported by Dr. Alexis during 2017 and/or 2018. Please note that this information may differ from information posted on corporate sites due to timing or classification differences.
- Allergan, Inc.
- Amgen Inc.
- Galderma S.A.
- Johnson & Johnson Services, Inc.
- Proctor & Gamble
Industry-Sponsored Lectures: MSSM faculty occasionally give lectures at events sponsored by industry, but only if the events are free of any marketing purpose
- Cipla Global Limited
Scientific Advisory Board:
- Allergan, Inc.
- Amgen Inc.
- Galderma S.A.
- LEO Pharma Inc.
- Suneva Medical, Inc.
- Valeant Pharmaceuticals International, Inc.
Mount Sinai's faculty policies relating to faculty collaboration with industry are posted on our website. Patients may wish to ask their physician about the activities they perform for companies.
Physicians who provide services at hospitals and facilities in the Mount Sinai Health System might not participate in the same health plans as those Mount Sinai hospitals and facilities (even if the physicians are employed or contracted by those hospitals or facilities).
Information regarding insurance participation and billing by this physician may be found on this page, and can also be obtained by contacting this provider directly. Because physicians insurance participation can change, the insurance information on this page may not always be up-to-date. Please contact this physician directly to obtain the most up-to-date insurance information.
Insurance and health plan networks that the various Mount Sinai Health System hospitals and facilities participate in can be found on the Mount Sinai Health System website.